Intellia Therapeutics (NTLA) Misses Q1 EPS by 86c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.96), $0.86 worse than the analyst estimate of ($1.10). Revenue for the quarter came in at $0 versus the consensus estimate of $8.54 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Hour Loop, Inc. (HOUR) Reports Q2 EPS of $0.03
• Owlet (OWLT) Tops Q2 EPS by 9c